Stability of 188Re Labeled Antibody for Radioimmunotherapy and the Effect of Stabilizing Agents / 대한핵의학회잡지

No abstract available.

Correlation of GLUT-1 Expression and F-18-FDG Uptake on Positron Emission Tomography in Breast Carcinoma / 대한암학회지

PURPOSE: Fluorine-18-fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) has been proven to be useful in the detection of breast cancer. However, the degree of FDG uptake was variable. In this study, we evaluated the relationship between glucose transporter-1 (GLUT-1) expression with the FDG uptake in patients with breast cancer. MATERIALS AND METHODS: 15 patients with proven breast cancer underwent F-18-FDG PET. After surgical resection, anti-GLUT-1 immunohistochemical staining was performed in tumor tissues to measure the GLUT-1 expression. We evaluated the correlation between semi-quantitative FDG uptake by standardized uptake value (SUV) and GLUT-1 expression. RESULTS: In total 15 patients, there was no significant correlation between SUV and GLUT-1 expression. We separated the patients into two groups according to the tumor size. In the group of large tumor (short diameter > or =2 cm), there was no significant correlation. However, in the group of small tumor (short diameter <2 cm), there was a significant correlation between the FDG uptake and GLUT-1 expression (rho=0.812, p=0.047). CONCLUSION: GLUT-1 expression can influence the FDG uptake in the small breast cancers. For large breast cancers, other factors as well as GLUT-1 expression may influence the FDG uptake.

The Relationship between F-18-FDG Uptake, Hexokinase Activity and Glut-1 Expression in Various Human Cancer Cell Lines / 대한핵의학회잡지

PURPOSE: To investigate the mechanisms related to F-18-FDG uptake by tumors, F-18-FDG accumulation was compared with glucose transporter-1 (Glut-1) expression and hexokinase activity in various human cancer cell lines. MATERAL AND METHODS: Human colon cancer (SNU-C2A, SNU-C4, SNU-C5), hepatocellular carcinoma (SNU-387, SNU-423, SNU-449), lung cancer (NCI-H522, NCI-H358, NCI- H1299), uterine cervical cancer (HeLa, HeLa 229, HeLa S3) and brain tumor (A172, Hs 683) cell lines were used. After 24 hr incubation of 5x105 cells, 37 kBq F-18-FDG was added and the uptake by cells at 10 min was measured using a gamma counter. Hexokinase activity was measured by continuous spectrophotometric rate determination. To measure mitochondrial hexokinase activity, mitochondrial fraction was separated by a high speed centrifuge. Immunohistochemical staining of Glut-1 was performed, and graded as 0, 1, 2, or 3 according to expression. RESULTS: There was difference among F-18-FDG uptake, total and mitochondrial hexokinase activity, and Glut-1 expression with different cancer cell lines. The correlations of F-18-FDG with total hexokinase and mitochondrial hexokinase activity were low (r=0.27 and 0.26, respectively). Glut-1 expression showed a good correlation with F-18-FDG uptake ((p)=0.81, p=0.0015). Previously, we reported no correlation of F-18-FDG uptake with hexokinase activity in colon cancer cell lines. Thus, when colon cancer cells were excluded, F-18-FDG uptake showed higher correlation with total hexokinase and mitochondrial hexokinase activity (r=0.81, p=0.0027 and r=0.81, p=0.0049, respectively). CONCLUSION: Both Glut-1 expression and hexokinase activity were contributing factors related to F-18-FDG accumulation in human cancer cell lines. The relative contribution of Glut-1 expression and hexokinase activity, however, was different among different cancer cell types.

Effect of Carrier on Labeling and Biodistribution of Re-188-Hydroxyethylidene diphosphonate / 대한핵의학회잡지

PURPOSE: Re-188-Hydroxyethylidene diphosphonate (HEDP) is a new cost-effective agent for systemic radioisotope therapy of metastatic bone pain. We investigated the influence of carrier for labeling and biodistribution of Re-188-HEDP using HEDP kit with or without carrier (KReO4). MATERALS AND METHODS: The kits (HEDP 15 mg, gentisic acid 4 mg and SnCl2.2H2O 4.5 mg) with or without carrier (KReO4 0.1 mg) were labeled with Re-188 solution, made available from an in-house generator by boiling for 15 min. We compared the labeling efficiency and stability of carrier-added and carrier-free preparations of Re-188-HEDP. Biodistribution and imaging studies of each preparation were performed in ICR mice (1.85~3.7 MBq/0.1 ml) and SD rats (74.1~85.2 MBq/0.5 ml). RESULTS: The carrier-added preparation showed high labeling efficiency (95% at pH 5) and high stability in serum (88%, 3 hr). However, the carrier-free preparation showed low labeling efficiency (59% at pH 5) and low stability (43%, 3 hr). The carrier-added preparation showed high uptake in bone and low uptake in stomach and kidneys. However, the carrier-free preparation showed lower uptake in bone and higher uptake in both stomach and kidneys, which is supposed to be due to released perrhenate. The carrier-added preparation also showed better images with higher skeletal accumulation, lower uptake in other organs and lower soft tissue uptake than the carrier-free preparation. CONCLUSION: The results of these studies clearly demonstrate that addition of carrier perrhenate is required for high labeling efficiency, stability, bone uptake and good image quality of Re-188-HEDP.